Advertisement

Document › Details
Evotec SE. (4/15/20). "Press Release: Just – Evotec Biologics Develops AI-driven Humanoid Antibody Library (“HAL”)". Seattle, WA.
![]() |
Organisation | Evotec SE (FSE: EVT, MDA X/TecDAX) |
Group | Evotec (Group) | |
Organisation 2 | Just – Evotec Biologics Inc. | |
Group | Evotec (Group) | |
![]() |
Product | HAL AI-driven humanoid antibody library |
Product 2 | artificial intelligence (AI) / machine learning (ML) | |
Just – Evotec Biologics announced today that the Company has compiled a library of a new class of humanoid antibodies using a novel, AI-derived approach. Antibodies are proteins produced and secreted by B-cells. As they bind to foreign substances that invade the body, such as pathogens and a plethora of other targets, they represent an important class of biologics-based therapeutics. However, patient accessibility is currently quite limited, as B-cells do not undergo selective pressure in vivo to produce antibodies with ideal biotherapeutic characteristics. Additionally, protein scientists have traditionally had to rely on the very limited scope of previously-discovered antibodies and their close variants to develop predictive models of complex antibody behaviour.
Just – Evotec Biologics’ data and laboratory scientists have developed a novel antibody library generation method using Generative Adversarial Networks (GANs), that enables controlled design of biological and structural features for therapeutic quality and developability. This approach creates a new class of AI-derived humanoid antibodies that mimic the diversity and properties of the human antibody repertoire while optimising the antibodies for development, manufacturing, and in use characteristics that make them better suited as biotherapeutics. HAL is expected to serve as a highly efficient starting point for drug discovery and development projects across a broad range of indications.
Click here to read a pre-print of the article at bioRxiv.
FORWARD LOOKING STATEMENTS
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.
Record changed: 2020-05-14 |
Advertisement

More documents for Evotec (Group)
- [1] Evotec SE. (2/9/21). "Press Release: Evotec and Related Sciences Enter Integrated Drug Discovery and Development Partnership". Hamburg....
- [2] Evotec SE. (12/21/20). "Press Release: Evotec Partners with Alloy Therapeutics to Expand Its Antibody Discovery Platform". Hamburg....
- [3] Evotec SE. (12/17/20). "Press Release: Evotec Achieves Key Milestones in Its Collaboration with Bristol Myers Squibb on Targeted Protein Degradation". Hamburg....
- [4] Evotec SE. (12/9/20). "Press Release: Evotec and Sartorius Partner with Start-up Curexsys on iPSC-based Exosome Approach". Hamburg....
- [5] Evotec SE. (11/24/20). "Press Release: Evotec and Rappta Therapeutics Enter Discovery and Development Partnership Focused on Oncology target". Hamburg....
- [6] Evotec SE. (11/17/20). "Press Release: Evotec and Storm Therapeutics Leverage INDiGO Platform to Progress Oncology Project towards Clinical Studies". Hamburg....
- [7] Eternygen GmbH. (10/26/20). "Press Release: Eternygen Announces the First Closing of its Series A2 Funding Round". Berlin....
- [8] Evotec SE. (10/13/20). "Press Release: Mubdala Investment Company and Novo Holdings A/S Invest €250m in Evotec SE". Hamburg....
- [9] Evotec SE. (10/8/20). "Press Release: Evotec Achieves Milestone in Neurodegeneration Collaboration with Bristol Myers Squibb". Hamburg....
- [10] Evotec SE. (9/14/20). "Press Release: Evotec and BIOASTER Partner to Build a Technology and Innovation Hub in Lyon". Hamburg....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement
![Picture [iito] Back into Ad 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-back-into-ad.jpg)
» top